{'fraction_non_alphanumeric': 0.02406015037593985, 'fraction_numerical': 0.0015037593984962407, 'mean_word_length': 6.318681318681318, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission

Lifelong immunosuppression for Crohn’s disease has been associated with increased morbidity; opportunistic infections, lymphomas, nonmelanoma skin cancers and allergic/hypersensitivity reactions [1]. Many Crohn’s disease patients are on combination therapy with an immunomodulator and anti-TNF medication. It is unclear what happens when Crohn’s disease treatment is stopped in patients who have achieved remission. Several studies have investigated the outcomes of stopping immunomodulator therapy or antiTNF therapy in patients who successfully achieve remission.